Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis

Cancer Science

Volumn 100, Issue 8, 2009, Pages 1421-1428

  Yoshihara, Kosuke ^a   Tajima, Atsushi ^b   Komata, Dai ^a   Yamamoto, Tadashi ^a   Kodama, Shoji ^c   Fujiwara, Hiroyuki ^d   Suzuki, Mitsuaki ^d   Onishi, Yoshitaka ^e   Hatae, Masayuki ^e   Sueyoshi, Kazunobu ^e   Fujiwara, Hisaya ^f   Kudo, Yoshiki ^f   Inoue, Ituro ^b   Tanaka, Kenichi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e Kagoshima City Hospital   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ 2; COLLAGEN TYPE 16; HOMEODOMAIN PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ZINC FINGER E BOX BINDING HOMEOBOX PROTEIN 2;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

CYSTADENOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; REPRESSOR PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67650712196     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01204.x     Document Type: Article

References (43)

1. Disaia PJ, Creasman WT. Epithelial ovarian cancer. In: Disaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology, 6th edn. St Louis: Mosby, 2002; 289-350.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-29.
3. Agarwal R, Kaye SB. Expression profiling and individualization of treatment for ovarian cancer. Curr Opin Pharmacol 2006; 6: 345-9.
4. Olivier RI, van Beurden M, van't Veer LJ. The role of gene expression profiling in the clinical management of ovarian cancer. Eur J Cancer 2006; 42: 2930-8.
5. Fehrmann RS, Li XY, van der Zee AG et al. Profiling studies in ovarian cancer: A review. Oncologist 2007; 12: 960-6.
6. Spentzos D, Levine DA, Ramoni MF et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700-10.
7. Berchuck A, Iversen ES, Lancaster JM et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11: 3686-96.
8. Hartmann LC, Lu KH, Linette GP et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005; 11: 2149-55.
9. Bonome T, Levine DA, Shih J et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008; 68: 5478-86.
10. Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 913-20.
11. Dressman HK, Berchuck A, Chan G et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25: 517-25.
12. Newton TR, Parsons PG, Lincoln DJ et al. Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. Int J Cancer 2006; 119: 875-83.
13. Partheen K, Levan K, Osterberg L, Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 2006; 42: 2846-54.
14. Okamoto A, Nikaido T, Ochiai K et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11: 6030-9.
15. Donninger H, Bonome T, Radonovich M et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23: 8065-77.
16. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 1053-65.
17. Bonome T, Lee JY, Park DC et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602-12.
18. Shridhar V, Lee J, Pandita A et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 2001; 61: 5895-904.
19. De Cecco L, Marchionni L, Gariboldi M et al. Gene expression profiling of advanced ovarian cancer: Characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004; 23: 8171-83.
20. Lancaster JM, Dressman HK, Clarke JP et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006; 16: 1733-45.
21. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shin IeM. Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198: 351-6.
22. Thiery JP. Epithelial mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
23. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-28.
24. FIGO Cancer Committee. Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 1986; 25: 383-5.
25. Amikura T, Sekine M, Hirai Y et al. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan. Gynecol Oncol 2006; 100: 365-71.
26. Sekine M, Nagata H, Tsuji S et al. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: Two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 2001; 7: 3144-50.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
28. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA 2004; 101: 4164-9.
29. Okada H, Tajima A, Shichiri K, Tanaka A, Tanaka K, Inoue I. Genome-wide expression of azoospermia testes demonstrates a specific profile and implicates ART3 in genetic susceptibility. PLoS Genet 2008; 4: E26.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001; 25: 402-8.
31. Inamura K, Fujiwara T, Hoshida Y et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 2005; 24: 7105-13.
32. DaraïE, Scoazec JY, Walker-Combrouze F et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: A clinicopathologic study of 60 cases. Hum Pathol 1997; 28: 922-8.
33. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 2004; 15: 1535-42.
34. Voutilainen KA, Anttila MA, Sillanpää SM et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 2006; 59: 460-7.
35. Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Höfler H, Becker KF. The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 2007; 98: 489-95.
36. Imamichi Y, König A, Gress T, Menke A. Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene 2007; 26: 2381-5.
37. Gao Y, Church G. Improving molecular cancer class discovery through sparse non-negative matrix factorization. Bioinformatics 2005; 21: 3970-5.
38. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008; 5: 577-87.
39. Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-208.
40. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005; 24: 8277-90.
41. Imai T, Horiuchi A, Wang C et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003; 163: 1437-47.
42. Hosono S, Kajiyama H, Terauchi M et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 2007; 96: 314-20.
43. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.